We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Medtronic Initiates BTK Study on DCB for PAD Cure in Europe
Read MoreHide Full Article
Medical device major Medtronic plc (MDT - Free Report) recently initiated the IN.PACT below-the-knee (BTK) study to evaluate the effectiveness of a drug-coated balloon (DCB) for treatment of peripheral arterial disease (PAD). This study will assess the IN.PACT 0.014 paclitaxel-coated percutaneous transluminal angioplasty (PTA) balloon catheter, which is an investigational device using Medtronic’s unique IN.PACT Admiral drug coating technology.
IN.PACT BTK is a prospective, randomized and unique study that will enroll almost 60 patients at four sites in Europe. The study has an important angiographic measure of drug effectiveness in patients who received treatment with the IN.PACT 0.014 DCB compared to standard PTA. The assessment will also include a wound care protocol, which will ensure additional safety controls, routine check-ups and standard monitoring by qualified wound care professionals of patients.
The procedure was recently performed successfully on a patient with critical limb ischemia (CLI) for the first time. CLI with below-the-knee PAD is related to the risk of non-healing wound ulcers and amputation. This complex disease is one of the clinical challenges for physicians in the clinical vascular community.
Clinicians maintain that the new study marks a milestone in identifying a treatment option for below-the-knee PAD. Given the chronic nature of the disease, there is a critical need for safe and durable treatment options that could reduce the need of target lesions revascularization and major amputation. Thus, Medtronic’s Aortic & Peripheral Vascular (APV) division is working with the clinical community to further understand the complexity of this disease and build on the emerging body of scientific knowledge regarding use of DCBs below the knee.
As per a Grand View Research report, the global knee implants market is expected to grow at a CAGR of 4.0% till 2024. Medtronic is striving to cash in on the untapped potential of this growing market.
Stock Performance
For the last one month, Medtronic has been trading above the Zacks categorized Medical - Products industry. The stock gained 8.7%, higher than the 3.5% gain of the broader industry. The company’s better-than-expected results in the fiscal third quarter are expected to boost the share price. Medtronic’s APV revenues in the reported quarter rose 6% to $426 million, driven by high-single digit growth in Peripheral Vascular and mid-single digit growth in Aortic.
Key Industry Players
Some key stocks in the medical product sector are Inogen, Inc. (INGN - Free Report) , Bovie Medical Corporation and Neogen Corp. (NEOG - Free Report) .
Inogen gained over 100% in the last one year in comparison to the S&P 500’s gain of 16.9%. The company has a stellar four-quarter average earnings surprise of over 49.08%.
Bovie Medical surged 74.6% in the last one year in comparison to the S&P 500. It has a four-quarter average earnings surprise of 28.7%.
Neogen gained 22.4% in the past one year, better than the S&P 500 mark. The stock has an impressive long-term earnings growth rate of 16.7% for the next five years compared to the industry average of 15.2%.
5 Trades Could Profit "Big-League" from Trump Policies
If the stocks above spark your interest, wait until you look into companies primed to make substantial gains from Washington's changing course.
Today Zacks reveals 5 tickers that could benefit from new trends like streamlined drug approvals, tariffs, lower taxes, higher interest rates, and spending surges in defense and infrastructure. See these buy recommendations now >>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Medtronic Initiates BTK Study on DCB for PAD Cure in Europe
Medical device major Medtronic plc (MDT - Free Report) recently initiated the IN.PACT below-the-knee (BTK) study to evaluate the effectiveness of a drug-coated balloon (DCB) for treatment of peripheral arterial disease (PAD). This study will assess the IN.PACT 0.014 paclitaxel-coated percutaneous transluminal angioplasty (PTA) balloon catheter, which is an investigational device using Medtronic’s unique IN.PACT Admiral drug coating technology.
IN.PACT BTK is a prospective, randomized and unique study that will enroll almost 60 patients at four sites in Europe. The study has an important angiographic measure of drug effectiveness in patients who received treatment with the IN.PACT 0.014 DCB compared to standard PTA. The assessment will also include a wound care protocol, which will ensure additional safety controls, routine check-ups and standard monitoring by qualified wound care professionals of patients.
The procedure was recently performed successfully on a patient with critical limb ischemia (CLI) for the first time. CLI with below-the-knee PAD is related to the risk of non-healing wound ulcers and amputation. This complex disease is one of the clinical challenges for physicians in the clinical vascular community.
Clinicians maintain that the new study marks a milestone in identifying a treatment option for below-the-knee PAD. Given the chronic nature of the disease, there is a critical need for safe and durable treatment options that could reduce the need of target lesions revascularization and major amputation. Thus, Medtronic’s Aortic & Peripheral Vascular (APV) division is working with the clinical community to further understand the complexity of this disease and build on the emerging body of scientific knowledge regarding use of DCBs below the knee.
As per a Grand View Research report, the global knee implants market is expected to grow at a CAGR of 4.0% till 2024. Medtronic is striving to cash in on the untapped potential of this growing market.
Stock Performance
For the last one month, Medtronic has been trading above the Zacks categorized Medical - Products industry. The stock gained 8.7%, higher than the 3.5% gain of the broader industry. The company’s better-than-expected results in the fiscal third quarter are expected to boost the share price. Medtronic’s APV revenues in the reported quarter rose 6% to $426 million, driven by high-single digit growth in Peripheral Vascular and mid-single digit growth in Aortic.
Key Industry Players
Some key stocks in the medical product sector are Inogen, Inc. (INGN - Free Report) , Bovie Medical Corporation and Neogen Corp. (NEOG - Free Report) .
Inogen gained over 100% in the last one year in comparison to the S&P 500’s gain of 16.9%. The company has a stellar four-quarter average earnings surprise of over 49.08%.
Bovie Medical surged 74.6% in the last one year in comparison to the S&P 500. It has a four-quarter average earnings surprise of 28.7%.
Neogen gained 22.4% in the past one year, better than the S&P 500 mark. The stock has an impressive long-term earnings growth rate of 16.7% for the next five years compared to the industry average of 15.2%.
5 Trades Could Profit "Big-League" from Trump Policies
If the stocks above spark your interest, wait until you look into companies primed to make substantial gains from Washington's changing course.
Today Zacks reveals 5 tickers that could benefit from new trends like streamlined drug approvals, tariffs, lower taxes, higher interest rates, and spending surges in defense and infrastructure. See these buy recommendations now >>